Sweden's Dental and Pharmaceutical Benefits Agency, the TLV, has presented its review of lipid-lowering drugs, effective June 1, in a ruling expected to save up to 170.0 million kronor ($19.9 million) per year. The Agency said: "the funds can, in part, be used to improve the treatment of stroke within the health care system according to the new guidelines." The TLV's reimbursement decisions mean that a Swedish patient pays a maximum of 1,800 kronor per year for prescription drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze